ACM
LAB icon

Advent Capital Management’s Standard BioTools LAB Stock Holding History

Advent Capital Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-200
Closed -$15K – 538
2015
Q2 		$15K Buy
+200
New +$6.31K ﹤0.01% 489

Other funds holding LAB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Advent Capital Management's LAB Position: Q3 2015 in Review

Advent Capital Management sold out of Standard BioTools (LAB) in Q3 2015, closing a stake of 2,500 shares — an estimated $61K sold.

Advent Capital Management first reported a position in LAB in Q2 2014 and held it in 3 quarters. The position peaked at $261K in Q2 2014. 109 funds tracked by Wall St. Rank hold LAB as of Q3 2015.

  • Advent Capital Management reported no remaining Standard BioTools position as of Q3 2015 after selling out during the quarter.
  • Advent Capital Management sold 2,500 Standard BioTools shares in Q3 2015, an estimated $61K.
  • Advent Capital Management first reported a position in Standard BioTools in Q2 2014 and held it in 3 quarters.
  • Advent Capital Management's Standard BioTools position peaked at $261K in Q2 2014.
  • 109 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2015.

Based on Advent Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.